Everett Collection / Shutterstock.com
3 November 2014AmericasJason Rutt
Insurance companies v AstraZeneca
“Pay for delay” agreements have been a hot topic on both sides of the Atlantic for some time. These are patent dispute settlements in which a generic manufacturer acknowledges the patent of the originator pharmaceutical company and agrees not to market its generic for a specific period of time. In return, the patent holder makes a payment to the generic company.
